IL297149A - Compounds and Methods for Splicing Regulation - Google Patents
Compounds and Methods for Splicing RegulationInfo
- Publication number
- IL297149A IL297149A IL297149A IL29714922A IL297149A IL 297149 A IL297149 A IL 297149A IL 297149 A IL297149 A IL 297149A IL 29714922 A IL29714922 A IL 29714922A IL 297149 A IL297149 A IL 297149A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- heterocyclyl
- heteroaryl
- aryl
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Replacement Of Web Rolls (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063007327P | 2020-04-08 | 2020-04-08 | |
| US202063043920P | 2020-06-25 | 2020-06-25 | |
| US202063072873P | 2020-08-31 | 2020-08-31 | |
| US202063126493P | 2020-12-16 | 2020-12-16 | |
| PCT/US2021/026477 WO2021207550A1 (en) | 2020-04-08 | 2021-04-08 | Compounds and methods for modulating splicing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297149A true IL297149A (en) | 2022-12-01 |
Family
ID=75747105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297149A IL297149A (en) | 2020-04-08 | 2021-04-08 | Compounds and Methods for Splicing Regulation |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20240287097A1 (https=) |
| EP (2) | EP4132935A1 (https=) |
| JP (2) | JP2023520925A (https=) |
| KR (2) | KR20230005210A (https=) |
| CN (2) | CN116134036A (https=) |
| AU (2) | AU2021253571A1 (https=) |
| BR (2) | BR112022020337A2 (https=) |
| CA (2) | CA3175205A1 (https=) |
| CL (1) | CL2022002779A1 (https=) |
| CO (1) | CO2022015926A2 (https=) |
| CR (1) | CR20220567A (https=) |
| IL (1) | IL297149A (https=) |
| MX (2) | MX2022012676A (https=) |
| WO (2) | WO2021207550A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019028440A1 (en) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN114126613A (zh) | 2019-02-05 | 2022-03-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| CN113661162A (zh) | 2019-02-06 | 2021-11-16 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| BR112022023025A2 (pt) | 2020-05-13 | 2023-03-28 | Chdi Foundation Inc | Moduladores de htt para tratar doença de huntington |
| WO2022194802A1 (en) * | 2021-03-17 | 2022-09-22 | F. Hoffmann-La Roche Ag | New thiadiazolopyrimidone derivatives |
| BR112023018466A2 (pt) * | 2021-03-17 | 2023-10-10 | Hoffmann La Roche | Derivados de tiazolopirimidinona |
| CN116997555A (zh) * | 2021-03-17 | 2023-11-03 | 豪夫迈·罗氏有限公司 | 新颖噻吩并嘧啶酮衍生物 |
| WO2023064879A1 (en) * | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
| US12281116B2 (en) | 2021-11-17 | 2025-04-22 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
| AU2022398247A1 (en) * | 2021-11-24 | 2024-06-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| CN115112899B (zh) * | 2022-06-15 | 2024-08-16 | 四川大学华西医院 | 检测羧肽酶a4的试剂和/或系统在制备恶性胸腔积液筛查产品中的用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB242502A (en) * | 1925-03-10 | 1925-11-12 | Hoe & Co R | Improvements in stapling and folding mechanism |
| JPS57142989A (en) * | 1981-02-27 | 1982-09-03 | Dai Ichi Seiyaku Co Ltd | Thiazolopyrimidine derivative |
| JPS58177997A (ja) * | 1982-04-12 | 1983-10-18 | Dai Ichi Seiyaku Co Ltd | チアジアゾロピリミジノン誘導体 |
| DE3763282D1 (de) * | 1986-03-19 | 1990-07-26 | Kumiai Chemical Industry Co | Fungizide zur verwendung in der landwirtschaft und im gartenbau. |
| TW449600B (en) * | 1994-04-19 | 2001-08-11 | Takeda Chemical Industries Ltd | Condensed-ring thiophene derivatives, their production and use |
| US6153614A (en) * | 1998-07-16 | 2000-11-28 | Abbott Laboratories | Piperazinyl pyrimidine dione compounds selective for adrenoceptors |
| AR038118A1 (es) * | 2002-01-14 | 2004-12-29 | Upjohn Co | Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales |
| US20060194871A1 (en) * | 2003-04-11 | 2006-08-31 | Barvian Kevin K | Heterocyclic mchr1 antagoists |
| US20050176738A1 (en) * | 2003-11-07 | 2005-08-11 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
| US7745447B2 (en) * | 2005-10-26 | 2010-06-29 | Bristol-Myers Squibb Company | Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists |
| AR056155A1 (es) * | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
| KR100846988B1 (ko) * | 2006-03-06 | 2008-07-16 | 제일약품주식회사 | 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물 |
| WO2008057601A2 (en) * | 2006-11-08 | 2008-05-15 | The Rockefeller University | Organic compounds |
| CA2805724A1 (en) * | 2010-07-16 | 2012-01-19 | Rockefeller University | Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines |
| EP2721036B1 (en) * | 2011-06-15 | 2015-07-22 | Takeda GmbH | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c]isoquinoline compounds |
| US20130102601A1 (en) * | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| EP2804610B1 (en) * | 2012-01-16 | 2018-10-31 | The Rockefeller University | Organic compounds |
| DK2812004T3 (en) | 2012-02-10 | 2018-10-15 | Ptc Therapeutics Inc | COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| CA2946702C (en) * | 2014-04-23 | 2022-06-28 | Mitsubishi Tanabe Pharma Corporation | Bicyclic or tricyclic heterocyclic compound |
| SI3143025T1 (sl) * | 2014-05-15 | 2020-01-31 | F. Hoffmann-La Roche Ag | Spojine za zdravljenje spinalne mišične atrofije |
| US10294243B2 (en) * | 2014-06-05 | 2019-05-21 | Bayer Cropscience Aktiengesellschaft | Bicyclic compounds as pesticides |
| WO2016128343A1 (en) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment of cancer |
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| CN106279211B (zh) * | 2015-06-03 | 2020-09-15 | 北京大学 | 一种噻唑并嘧啶酮化合物及其制备方法和应用 |
| JP6791717B2 (ja) * | 2015-10-22 | 2020-11-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AR106472A1 (es) * | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| CA3037642A1 (en) * | 2016-09-23 | 2018-03-29 | Bayer Aktiengesellschaft | N 3 -cyclically substituted thienouraciles and use thereof |
| EA201991309A1 (ru) | 2016-11-28 | 2019-11-29 | Способы модуляции сплайсинга рнк | |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| EA201992780A1 (ru) * | 2017-06-21 | 2020-06-02 | ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи | Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания |
| WO2019028440A1 (en) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
| KR20200057071A (ko) | 2017-09-25 | 2020-05-25 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물 |
| CA3094988A1 (en) * | 2018-03-30 | 2019-10-03 | Biotheryx, Inc. | Thienopyrimidinone compounds |
| CN112272666A (zh) | 2018-04-10 | 2021-01-26 | 斯基霍克疗法公司 | 用于治疗癌症的化合物 |
| BR112020026637A2 (pt) * | 2018-06-27 | 2021-03-30 | Reborna Biosciences, Inc. | Agente profilático ou terapêutico para atrofia muscular espinhal |
| BR112023018466A2 (pt) * | 2021-03-17 | 2023-10-10 | Hoffmann La Roche | Derivados de tiazolopirimidinona |
| WO2022194802A1 (en) * | 2021-03-17 | 2022-09-22 | F. Hoffmann-La Roche Ag | New thiadiazolopyrimidone derivatives |
-
2021
- 2021-04-08 KR KR1020227039044A patent/KR20230005210A/ko active Pending
- 2021-04-08 MX MX2022012676A patent/MX2022012676A/es unknown
- 2021-04-08 AU AU2021253571A patent/AU2021253571A1/en active Pending
- 2021-04-08 WO PCT/US2021/026477 patent/WO2021207550A1/en not_active Ceased
- 2021-04-08 JP JP2022561469A patent/JP2023520925A/ja active Pending
- 2021-04-08 JP JP2022561468A patent/JP7797407B2/ja active Active
- 2021-04-08 CN CN202180040768.XA patent/CN116134036A/zh active Pending
- 2021-04-08 US US17/917,868 patent/US20240287097A1/en active Pending
- 2021-04-08 US US17/917,842 patent/US20240279239A1/en active Pending
- 2021-04-08 EP EP21722687.7A patent/EP4132935A1/en active Pending
- 2021-04-08 CA CA3175205A patent/CA3175205A1/en active Pending
- 2021-04-08 BR BR112022020337A patent/BR112022020337A2/pt unknown
- 2021-04-08 IL IL297149A patent/IL297149A/en unknown
- 2021-04-08 WO PCT/US2021/026435 patent/WO2021207530A1/en not_active Ceased
- 2021-04-08 CA CA3175193A patent/CA3175193A1/en active Pending
- 2021-04-08 KR KR1020227039049A patent/KR20230004575A/ko active Pending
- 2021-04-08 CR CR20220567A patent/CR20220567A/es unknown
- 2021-04-08 BR BR112022020418A patent/BR112022020418A2/pt active Search and Examination
- 2021-04-08 MX MX2022012677A patent/MX2022012677A/es unknown
- 2021-04-08 EP EP21722693.5A patent/EP4132936A1/en active Pending
- 2021-04-08 AU AU2021251220A patent/AU2021251220A1/en active Pending
- 2021-04-08 CN CN202180040958.1A patent/CN116096725A/zh active Pending
-
2022
- 2022-10-07 CL CL2022002779A patent/CL2022002779A1/es unknown
- 2022-11-04 CO CONC2022/0015926A patent/CO2022015926A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023520925A (ja) | 2023-05-22 |
| EP4132936A1 (en) | 2023-02-15 |
| CR20220567A (es) | 2023-01-13 |
| EP4132935A1 (en) | 2023-02-15 |
| CA3175193A1 (en) | 2021-10-14 |
| KR20230005210A (ko) | 2023-01-09 |
| JP2023520924A (ja) | 2023-05-22 |
| CL2022002779A1 (es) | 2023-04-28 |
| AU2021251220A1 (en) | 2022-11-03 |
| BR112022020418A2 (pt) | 2023-05-02 |
| BR112022020337A2 (pt) | 2022-12-13 |
| CO2022015926A2 (es) | 2022-11-29 |
| JP7797407B2 (ja) | 2026-01-13 |
| WO2021207550A1 (en) | 2021-10-14 |
| WO2021207530A8 (en) | 2021-12-02 |
| WO2021207530A1 (en) | 2021-10-14 |
| MX2022012676A (es) | 2023-01-11 |
| US20240287097A1 (en) | 2024-08-29 |
| AU2021253571A1 (en) | 2022-11-10 |
| MX2022012677A (es) | 2023-01-11 |
| KR20230004575A (ko) | 2023-01-06 |
| US20240279239A1 (en) | 2024-08-22 |
| CA3175205A1 (en) | 2021-10-14 |
| CN116134036A (zh) | 2023-05-16 |
| CN116096725A (zh) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7797407B2 (ja) | スプライシングを調節するための化合物及び方法 | |
| AU2021228284A1 (en) | Compounds and methods for modulating splicing | |
| IL297137A (en) | Splicing Modulation Compounds and Methods | |
| WO2021174170A9 (en) | Pyridazine derivatives for modulating nucleic acid splicing | |
| IL299543A (en) | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases | |
| EP4416156A1 (en) | Compounds and methods for modulating nucleic acid splicing | |
| IL311132A (en) | Splicing Modulation Compounds and Methods | |
| WO2024259017A1 (en) | Compounds and methods for modulating splicing | |
| WO2024259015A1 (en) | Compounds and methods for modulating splicing | |
| EP4395889A1 (en) | Compounds and methods for modulating splicing |